BeauBrain Healthcare
BeauBrain Healthcare develops AI-based tools and digital therapeutics for early detection, risk prediction, and prevention of Alzheimer’s disease. The company focuses on quantitative neuroimaging (PET/CT and 2D MRI), tablet- and mobile-based cognitive assessment and training, clinical validation through published studies, and integration of imaging with genomic and cognitive data to enable precision brain-health services.
Industries
Nr. of Employees
small (1-50)
Products
Amyloid PET quantification software (PET/CT)
Software tool for automated regional quantification of amyloid PET scans, reporting standardized metrics to aid diagnosis and staging.
2D MRI atrophy analysis and biomarker prediction software
Deep-learning based software that quantifies atrophy from 2D MRI and predicts biomarker positivity (amyloid/tau), brain age, and dementia risk scores.
Tablet-based cognitive screening solution
Digital cognitive screening application for tablets covering multiple cognitive domains for clinical screening and monitoring.
Mobile cognitive training app and managed program
Mobile trainer for multi-domain cognitive exercises with gamification, clinician management, and group activities for prevention and rehabilitation.
Amyloid PET quantification software (PET/CT)
Software tool for automated regional quantification of amyloid PET scans, reporting standardized metrics to aid diagnosis and staging.
2D MRI atrophy analysis and biomarker prediction software
Deep-learning based software that quantifies atrophy from 2D MRI and predicts biomarker positivity (amyloid/tau), brain age, and dementia risk scores.
Tablet-based cognitive screening solution
Digital cognitive screening application for tablets covering multiple cognitive domains for clinical screening and monitoring.
Mobile cognitive training app and managed program
Mobile trainer for multi-domain cognitive exercises with gamification, clinician management, and group activities for prevention and rehabilitation.
Services
Quantitative PET/CT amyloid analysis service
Analytical service that quantifies regional amyloid burden from PET/CT images and reports standardized metrics for clinical interpretation.
2D MRI atrophy quantification and dementia risk prediction
Software analysis of routine 2D MRI to quantify regional atrophy and predict biomarker positivity, dementia risk indices, brain age, and prognosis.
Tablet-based cognitive screening deployment
Implementation and support for a tablet computer-based cognitive screening test evaluating multiple cognitive domains for screening and monitoring.
Mobile cognitive training and managed care programs
Mobile app-based cognitive training programs with clinician-managed options (1:1 neuropsychologist support), group activities, and home-based regimens aimed at prevention and cognitive improvement.
Clinical validation and research collaboration
Conducting and supporting clinical studies, RCTs, and publications to validate digital assessments and cognitive training interventions.
Quantitative PET/CT amyloid analysis service
Analytical service that quantifies regional amyloid burden from PET/CT images and reports standardized metrics for clinical interpretation.
2D MRI atrophy quantification and dementia risk prediction
Software analysis of routine 2D MRI to quantify regional atrophy and predict biomarker positivity, dementia risk indices, brain age, and prognosis.
Tablet-based cognitive screening deployment
Implementation and support for a tablet computer-based cognitive screening test evaluating multiple cognitive domains for screening and monitoring.
Mobile cognitive training and managed care programs
Mobile app-based cognitive training programs with clinician-managed options (1:1 neuropsychologist support), group activities, and home-based regimens aimed at prevention and cognitive improvement.
Clinical validation and research collaboration
Conducting and supporting clinical studies, RCTs, and publications to validate digital assessments and cognitive training interventions.
Expertise Areas
- Neuroimaging analysis for Alzheimer’s biomarkers
- AI/ML for medical image quantification
- Digital cognitive assessment and screening
- Mobile digital therapeutics for cognitive training
Key Technologies
- Deep learning for image analysis
- Ensemble machine learning
- PET quantification metrics (SUVR, Centiloid)
- 2D MRI atrophy quantification